Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.13.11.33 extracted from

  • Miyata, J.; Yokokura, Y.; Moro, K.; Arai, H.; Fukunaga, K.; Arita, M.
    12/15-Lipoxygenase regulates IL-33-induced eosinophilic airway inflammation in mice (2021), Front. Immunol., 12, 687192.
    View publication on PubMed
Search for more literature for 1.13.11.33

Application

Application Comment Organism
medicine application of 14(S)-hydroxy docosahexaenoic acid suppresses IL-33-mediated eosinophilic inflammation in 12/15-LOX-deficient mice. 14(S)-hydroxy docosahexaenoic acid and 10(S),17(S)-dihydroxy docosahexaenoic acid markedly attenuate ILC2 proliferation and cytokine production at micromolar concentration in vitro. Maresin 1 (MaR1) and resolvin D1 (RvD1), 12/15-LOX-derived specialized proresolving mediators (SPMs), inhibited cytokine production of ILC2s at nanomolar concentration Mus musculus

Organism

Organism UniProt Comment Textmining
Mus musculus P39654 cf. EC 1.13.11.33
-

Synonyms

Synonyms Comment Organism
12/15-LOX
-
 Mus musculus
Alox15
-
 Mus musculus

General Information

General Information Comment Organism
physiological function 12/15-LOX-deficient mice display augmented IL-33-induced lung inflammation, characterized by an increased number of infiltrated eosinophils and group 2 innate lymphoid cells in the airway. The levels of a series of 12/15-LOX-derived metabolites are significantly decreased, and application of 14(S)-hydroxy docosahexaenoic acid suppresses IL-33-mediated eosinophilic inflammation in 12/15-LOX-deficient mice. 14(S)-hydroxy docosahexaenoic acid and 10(S),17(S)-dihydroxy docosahexaenoic acid markedly attenuate ILC2 proliferation and cytokine production at micromolar concentration in vitro Mus musculus